Document Detail

Open-label study of clarithromycin in patients with undifferentiated connective tissue disease.
MedLine Citation:
PMID:  17023256     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: The macrolide family of antibiotics (erythromycin, clarithromycin, and others), have both antimicrobial and immunomodulatory effects. This study explored the effect of clarithromycin on the clinical course of patients with undifferentiated connective tissue disease (UCTD) in a 12-week open-label study. METHODS: The diagnosis of UCTD was based on symptoms/signs of connective tissue disease, and the presence of 1 or more positive autoimmune disease tests, but with insufficient criteria to make a definitive diagnosis. Screening and monthly follow-up visits over 12 weeks included the following: history and physical examination; concurrent medications; the 68/66 tender/swollen joint count; visual analog scores 0 to 100 mm for patient and physician global assessment of disease activity, and patient pain; antinuclear antibody panel, rheumatoid factor, erythrocyte sedimentation rate, C-reactive protein, and blood chemistry. RESULTS: Seven patients with rheumatic disease were treated with clarithromycin; 6 of 7 had symptomatic relief. Two subjects treated empirically before the decision to perform an open-label study responded favorably. Four of 5 patients who completed the prospective open-label study had mean maximal improvements from baseline of 78, 75, and 79% in patient pain, patient global, and investigator global assessments, respectively. Pain relief occurred as early as 1 week. Drug withdrawal with rechallenge in 2 patients resulted in flare followed by recapture of symptomatic relief. CONCLUSIONS: Clarithromycin, a macrolide antibiotic, led to clinical improvement in patients with UCTD. Efficacy and safety data support further investigation of macrolide antibiotic use as a primary or adjunctive treatment in various connective tissue diseases.
Roland W Moskowitz; Mary Lesko; Michele Hooper
Related Documents :
19479056 - Sustained remission after combination therapy with rituximab and etanercept in two pati...
20872586 - Kynurenine inhibits chondrocyte proliferation and is increased in synovial fluid of pat...
10372776 - Algodystrophy and its association with dupuytren's disease.
19590446 - Cryoglobulin crystal arthropathy in a patient with multiple myeloma.
8669736 - Prehospital endotracheal intubation of children by paramedics.
435646 - Granulocyte function during lithium therapy.
Publication Detail:
Type:  Case Reports; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Seminars in arthritis and rheumatism     Volume:  36     ISSN:  0049-0172     ISO Abbreviation:  Semin. Arthritis Rheum.     Publication Date:  2006 Oct 
Date Detail:
Created Date:  2006-10-06     Completed Date:  2007-01-18     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  1306053     Medline TA:  Semin Arthritis Rheum     Country:  United States    
Other Details:
Languages:  eng     Pagination:  82-7     Citation Subset:  IM    
Case Western Reserve University of Medicine, Cleveland, OH, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Arthritis / drug therapy,  pathology
Autoimmune Diseases / drug therapy,  pathology
Chondrocalcinosis / drug therapy,  pathology
Clarithromycin / administration & dosage*
Connective Tissue Diseases / drug therapy*,  pathology
Middle Aged
Patient Satisfaction
Protein Synthesis Inhibitors / administration & dosage*
Rheumatic Diseases / drug therapy*,  pathology
Reg. No./Substance:
0/Protein Synthesis Inhibitors; 81103-11-9/Clarithromycin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  An experimental pain model to investigate the specificity of the neurodynamic test for the median ne...
Next Document:  Systemic rheumatoid vasculitis: a review.